# Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fasting Conditions

> **NCT01523093** · NA · COMPLETED · sponsor: **Ranbaxy Laboratories Limited** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ondansetron

## Key facts

- **NCT ID:** NCT01523093
- **Lead sponsor:** Ranbaxy Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2006-07
- **Final completion:** 2006-10
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01523093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01523093, "Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fasting Conditions". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01523093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*